Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy

Contact the Supplier

Lead Product(s): BI 1467335

Therapeutic Area: Ophthalmology Product Name: BI 1467335

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 07, 2020

Details:

Boehringer Ingelheim decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.